登录
 机构网站
  1. 首页
  2. 情报产品
  3. 快讯详情

《MedRxiv，3月23日，Forecasting ultra-early intensive care strain from COVID-19 in England》

  • 来源专题：COVID-19科研动态监测
  • 编译者： zhangmin
  • 发布时间：2020-03-24

  • Forecasting ultra-early intensive care strain from COVID-19 in England

    Jacob Deasy, Emma Rocheteau, Katharina Kohler, Daniel J. Stubbs, Peitro Barbiero, Pietro Liò, Ari Ercole

    doi: https://doi.org/10.1101/2020.03.19.20039057

    Abstract

    The COVID-19 pandemic has led to unprecedented strain on intensive care unit (ICU) admission in parts of the world. Strategies to create surge ICU capacity requires complex local and national service reconfiguration and reduction or cancellation of elective activity. Theses measures require time to implement and have an inevitable lag before additional capacity comes on-line. An accurate short-range forecast would be helpful in guiding such difficult, costly and ethically challenging decisions. At the time this work began, cases in England were starting to increase.

    *注，本文为预印本论文手稿，是未经同行评审的初步报告，其观点仅供科研同行交流，并不是结论性内容，请使用者谨慎使用.

  • 原文来源：https://www.medrxiv.org/content/10.1101/2020.03.19.20039057v1
10浏览量
原文链接
相关报告

  • 《MedRxiv，5月3日，Clinical classifiers of COVID-19 infection from novel ultra-high-throughput proteomics》
    • 来源专题：COVID-19科研动态监测
    • 编译者：xuwenwhlib
    • 发布时间：2020-05-04
    • Clinical classifiers of COVID-19 infection from novel ultra-high-throughput proteomics Christoph B. Messner, Vadim Demichev, Daniel Wendisch, Laura Michalick, Matthew White, Anja Freiwald, Kathrin Textoris-Taube, Spyros I. Vernardis, Anna-Sophia Egger, Marco Kreidl, Daniela Ludwig, Christiane Kilian, Federica Agostini, Aleksej Zelezniak, Charlotte Thibeault, Moritz Pfeiffer, Stefan Hippenstiel, Andreas Hocke, Christof von Kalle, Archie Campbell, Caroline Hayward, David J. Porteous, Riccardo E. Marioni, Claudia Langenberg, Kathryn S. Lilley, Wolfgang M. Kuebler, Michael Muelleder, Christian Drosten, Martin Witzenrath, Florian Kurth, Leif Erik Sander, View ORCID ProfileMarkus Ralser doi: https://doi.org/10.1101/2020.04.27.20081810 Abstract The COVID-19 pandemic is an unprecedented global challenge. Highly variable in its presentation, spread and clinical outcome, novel point-of-care diagnostic classifiers are urgently required. Here, we describe a set of COVID-19 clinical classifiers discovered using a newly designed low-cost high-throughput mass spectrometry-based platform. Introducing a new sample preparation pipeline coupled with short-gradient high-flow liquid chromatography and mass spectrometry, our methodology facilitates clinical implementation and increases sample throughput and quantification precision. Providing a rapid assessment of serum or plasma samples at scale, we report 27 biomarkers that distinguish mild and severe forms of COVID-19, of which some may have potential as therapeutic targets. These proteins highlight the role of complement factors, the coagulation system, inflammation modulators as well as pro-inflammatory signalling upstream and downstream of Interleukin 6. Application of novel methodologies hence transforms proteomics from a research tool into a rapid-response, clinically actionable technology adaptable to infectious outbreaks.
    50浏览量
    原文链接

  • 《MedRxiv，4月3日，Simple model for Covid-19 epidemics - back-casting in China and forecasting in the US》
    • 来源专题：COVID-19科研动态监测
    • 编译者：xuwenwhlib
    • 发布时间：2020-04-05
    • Simple model for Covid-19 epidemics - back-casting in China and forecasting in the US View ORCID ProfileSlav W Hermanowicz doi: https://doi.org/10.1101/2020.03.31.20049486 This article is a preprint and has not been certified by peer review [what does this mean?]. It reports new medical research that has yet to be evaluated and so should not be used to guide clinical practice. Abstract In our previous work, we analyze, in near-real time, evolution of Covid-19 epidemic in China for the first 22 days of reliable data (up to February 6, 2020). In this work, we used the data for the whole 87 days (up to March 13, 2020) in China and the US data available till March 31 (day 70) for systematic evaluation of the logistic model to predict epidemic growth. We sequentially estimated sets of model parameters (maximum number of cases K, growth rate r, and half-time t0) and the epidemic "end time" t95 (defined as the time when the number of cases, predicted or actual, reached 95% of the maximum). The estimates of these parameters were done for sequences of reported cases growing daily (back-casting for China and forecasting for the US). In both countries, the estimates of K grew very much in time during the exponential and nearly exponential phases making longer term forecasting not reliable. For the US, the current estimate of the maximum number of cases K is about 265,000 but it is very likely that it will grow in the future. However, running estimates of the "end time" t95 were in a much smaller interval for China (60 - 70 days vs. the actual value of 67). For the US, the values estimated from the data sequences going back two weeks from now range from 70 to 80 days. If the behavior of the US epidemic is similar to the previous Chinese development, the number of reported cases could reach a maximum around April 10 to 14.
    85浏览量
    原文链接